Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Prediction: This Stock Could Double By 2031

Exelixis, a biotech company focused on cancer medicines, could potentially double by 2031. While its main product Cabometyx will face generic competition by early 2030, the company's promising pipeline candidate zanzalintinib could reach peak sales of $5 billion across multiple cancer indications, positioning it as a strong successor to drive future growth.

05/15/2026, 7:30 PM • The Motley Fool

Why Is Merck Stock Falling Tuesday?

Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial failed to meet primary endpoints for a triplet therapy combining Keytruda, Lenvima, and Welireg for advanced clear cell renal cell carcinoma. The failure caused Merck shares to fall 4.08%. However, the FDA approved Merck's new HIV treatment Idvynso on the same day, and analysts suggest alternative treatment strategies may still be viable.

04/21/2026, 1:42 PM • Benzinga

The Best Healthcare Stocks to Buy With $50 Right Now

The article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful Cabometyx therapy and promising pipeline candidates like zanzalintinib.

03/18/2026, 8:30 AM • The Motley Fool

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.

02/28/2026, 4:37 AM • The Motley Fool

InSilico Lands Drug Discovery Deal After Hong Kong IPO

InSilico Medicine, fresh from Hong Kong's biggest 2025 IPO raising HK$2.28 billion, announced a multi-year drug discovery partnership with French pharmaceutical company Servier worth up to $888 million. The deal leverages InSilico's AI platform for cancer drug development. Despite strong investor backing and rapid pipeline progress, the company faces profitability challenges with volatile revenue heavily dependent on partnership payments.

01/15/2026, 6:44 AM • Benzinga

2 Healthcare Stocks to Buy for 2026 and Beyond

The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx and an upcoming next-generation cancer medicine Zanzalintinib in phase 3 trials for metastatic colorectal cancer.

01/08/2026, 5:15 AM • The Motley Fool

2 Under-the-Radar Stocks to Buy Heading Into 2026

The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.

12/01/2025, 8:06 PM • The Motley Fool

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

10/31/2025, 7:00 AM • GlobeNewswire

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.

10/28/2025, 1:40 PM • Benzinga

The Ultimate Biotech Stock to Buy With $50 Right Now

Exelixis is a biotech company with a strong market position in cancer drugs, particularly kidney cancer treatment Cabometyx. The company is profitable, has promising drug candidates like zanzalintinib, and is well-positioned for future growth in oncology.

10/14/2025, 7:30 AM • The Motley Fool

Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight

The pancreatic endocrine tumor market is expected to grow significantly between 2025-2034, driven by novel therapies like Zanzalintinib, RYZ101, and Nab-sirolimus, which could transform treatment approaches for this rare cancer.

10/13/2025, 1:00 PM • GlobeNewswire

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years

Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.

09/30/2025, 4:10 AM • The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL

Pomerantz Law Firm is investigating potential securities fraud at Exelixis after the company reported lower-than-expected revenues and decided to discontinue a phase 3 clinical trial, causing its stock price to drop 16.78%.

08/09/2025, 11:40 AM • GlobeNewswire

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

The European Commission approved Cabometyx for treating adult patients with unresectable or metastatic neuroendocrine tumors who have progressed after prior systemic therapy, offering a new treatment option for patients with limited therapeutic alternatives.

07/24/2025, 1:41 PM • GlobeNewswire